199 related articles for article (PubMed ID: 21492126)
21. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Jeon MJ; Yu ES; Choi CW; Kim DS
Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
[TBL] [Abstract][Full Text] [Related]
22. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Paoluzzi L; Gonen M; Gardner JR; Mastrella J; Yang D; Holmlund J; Sorensen M; Leopold L; Manova K; Marcucci G; Heaney ML; O'Connor OA
Blood; 2008 Jun; 111(11):5350-8. PubMed ID: 18292288
[TBL] [Abstract][Full Text] [Related]
23. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.
Yazbeck VY; Li C; Grandis JR; Zang Y; Johnson DE
Oral Oncol; 2014 Feb; 50(2):120-7. PubMed ID: 24216166
[TBL] [Abstract][Full Text] [Related]
24. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
[TBL] [Abstract][Full Text] [Related]
25. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
[TBL] [Abstract][Full Text] [Related]
26. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.
Tsai PC; Hernandez-Ilizaliturri FJ; Bangia N; Olejniczak SH; Czuczman MS
Clin Cancer Res; 2012 Feb; 18(4):1039-50. PubMed ID: 22228637
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
29. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
30. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
32. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
[TBL] [Abstract][Full Text] [Related]
33. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
34. [Bortezomib and obatoclax for dual blockade of protein degradation pathways show synergistic anti-tumor effect in human acute T lymphoblastic leukemia cells].
Zhou D; Dai L; Liu X; Que F; Xu Y; Luo X; Zhu Y; Liu S; Li Y; Yu L
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Apr; 39(4):401-408. PubMed ID: 31068282
[TBL] [Abstract][Full Text] [Related]
35. BCL-6 protein is expressed in germinal-center B cells.
Cattoretti G; Chang CC; Cechova K; Zhang J; Ye BH; Falini B; Louie DC; Offit K; Chaganti RS; Dalla-Favera R
Blood; 1995 Jul; 86(1):45-53. PubMed ID: 7795255
[TBL] [Abstract][Full Text] [Related]
36. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
[TBL] [Abstract][Full Text] [Related]
39. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.
Cournoyer S; Addioui A; Belounis A; Beaunoyer M; Nyalendo C; Le Gall R; Teira P; Haddad E; Vassal G; Sartelet H
BMC Cancer; 2019 Oct; 19(1):1018. PubMed ID: 31664947
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
